Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins  Harel Dahari, Stephen M. Feinstone,

Slides:



Advertisements
Similar presentations
Volume 149, Issue 6, Pages (November 2015)
Advertisements

Volume 143, Issue 4, Pages e4 (October 2012)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 140, Issue 2, Pages e1 (February 2011)
Volume 141, Issue 4, Pages e6 (October 2011)
SMAD About Hepatitis C Virus Cell Entry and Liver Disease
The persistence of humoral and cellular immunities more than three decades after smallpox vaccination  S.-H. Kim, S.-G. Yeo, K.-H. Park, J.-W. Bang, H.-B.
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 141, Issue 3, Pages e4 (September 2011)
Volume 141, Issue 3, Pages (September 2011)
Volume 146, Issue 3, Pages e4 (March 2014)
Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection  Charles D. Howell, Thomas.
Volume 149, Issue 6, Pages (November 2015)
Volume 144, Issue 7, Pages e10 (June 2013)
Volume 140, Issue 3, Pages e3 (March 2011)
Effectiveness of Hepatitis B Treatment in Clinical Practice
Is HCV Infection a Neurologic Disorder?
Outcomes Among Living Liver Donors
Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection  Tobias Boettler, Robert Thimme  Gastroenterology 
Volume 128, Issue 2, Pages (February 2005)
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Volume 141, Issue 4, Pages e2 (October 2011)
Volume 133, Issue 4, Pages (October 2007)
Volume 132, Issue 2, Pages (February 2007)
Volume 133, Issue 3, Pages (September 2007)
Volume 134, Issue 5, Pages (May 2008)
Clinical Challenges and Images in GI
Volume 135, Issue 4, Pages (October 2008)
Volume 150, Issue 4, Pages (April 2016)
Volume 143, Issue 6, Pages e4 (December 2012)
Volume 154, Issue 4, Pages (March 2018)
Volume 151, Issue 5, Pages e4 (November 2016)
TLL1 rs Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C  Miya John, Mayada Metwally  Gastroenterology 
Volume 155, Issue 5, Pages e2 (November 2018)
Jean-Michel Pawlotsky  Gastroenterology 
Volume 141, Issue 2, Pages e1 (August 2011)
Volume 136, Issue 4, Pages (April 2009)
Volume 134, Issue 7, Pages e2 (June 2008)
Volume 136, Issue 7, Pages (June 2009)
A. Sidney Barritt, Michael W. Fried  Gastroenterology 
Volume 142, Issue 6, Pages e3 (May 2012)
Volume 128, Issue 4, Pages (April 2005)
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
Impact of New Hepatitis C Treatments in Different Regions of the World
Volume 145, Issue 3, Pages e11 (September 2013)
Volume 132, Issue 7, Pages (June 2007)
Volume 139, Issue 1, Pages e4 (July 2010)
Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review  Gennaro D’Amico, Juan Carlos Garcia-Pagan,
Volume 134, Issue 7, Pages e2 (June 2008)
Volume 140, Issue 7, Pages (June 2011)
Brendan Campbell, Benny Liu, Taft Bhuket, Robert J. Wong 
Interleukin-28b: A Key Piece of the Hepatitis C Virus Recovery Puzzle
Volume 152, Issue 1, Pages (January 2017)
Will There Be a Vaccine to Protect Against the Hepatitis C Virus?
Volume 148, Issue 3, Pages (March 2015)
Immune Quiescence and Hepatitis B Virus: Tolerance Has Its Limits
The Rise and Fall (and Rise?) of Endoscopic Anti-Reflux Procedures
The Dawning of a New Editorial Board for Gastroenterology
Christos Konstantakis, Maria Karamesini, Christos Triantos 
Meenakshi Bewtra, Chinyu Su, James D. Lewis 
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
Volume 156, Issue 3, Pages (February 2019)
Clinical Gastroenterology and Hepatology
Volume 155, Issue 6, Pages (December 2018)
Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?  Masaru Enomoto, Yoshiki Murakami,
Electronic Clinical Challenges and Images in GI
Controversies in Liver Transplantation for Hepatitis C
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
Antibody titers against surface antigens of B
A Female Patient With Persistent Epigastric Pain for 1 Week
Presentation transcript:

Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins  Harel Dahari, Stephen M. Feinstone, Marian E. Major  Gastroenterology  Volume 139, Issue 3, Pages 965-974 (September 2010) DOI: 10.1053/j.gastro.2010.05.077 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Comparison of HCV kinetics during primary and secondary infections in chimpanzees. (A) Maximum RNA titer detected in serum samples. (B) Time postchallenge (days) that maximum RNA titer was measured. (C) Duration of viremia (days; log2 scale). P < .05 indicates a difference between primary and secondary infections (exact Wilcoxon signed-rank test). Data obtained from Bassett et al,48 Bukh et al,49 Lanford et al,50 and Major et al.69 Gastroenterology 2010 139, 965-974DOI: (10.1053/j.gastro.2010.05.077) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Comparison of HCV kinetics in naïve, rechallenged, and vaccinated chimpanzees, regardless of infection outcome. (A) Maximum RNA titer detected in serum samples. (B) Time postchallenge (days) that maximum RNA titer was measured. Solid circles: naïve; open squares: rechallenged; solid triangles: vaccinated. Horizontal bars represent median values. P < .017 indicates a difference between groups (Mann–Whitney U Test). Gastroenterology 2010 139, 965-974DOI: (10.1053/j.gastro.2010.05.077) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Comparison of HCV kinetics in naïve, rechallenged, and vaccinated chimpanzees that cleared HCV. (A) Maximum RNA titer detected in serum samples. (B) Time postchallenge (days; log2 scale) that maximum RNA titer was measured. (C) Duration of viremia (days; log2 scale). Solid circles: naïve; open squares: rechallenged; solid triangles: vaccinated. Horizontal bars represent median values. P < .017 indicates a difference between groups (Mann–Whitney U test). Gastroenterology 2010 139, 965-974DOI: (10.1053/j.gastro.2010.05.077) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 Comparison of Elispot responses. (A) Rechallenged and vaccinated at challenge. (B) Rechallenged and vaccinated 2–4 weeks postchallenge. (C) Vaccinated animals at challenge. (D) Vaccinated animals 4 weeks postchallenge. Data are shown as interferon-γ spot forming units (SFU) per 106 peripheral blood mononuclear cells (PBMCs). (A and B): Open squares: rechallenged; solid triangles: vaccinated. (C and D): Open diamonds: persistent infections; solid diamonds: cleared infections. Horizontal lines represent median values. P < .05 indicates a difference between groups (Mann–Whitney U test). Gastroenterology 2010 139, 965-974DOI: (10.1053/j.gastro.2010.05.077) Copyright © 2010 AGA Institute Terms and Conditions